Monthly Replacement Orthokeratology for Myopia Control in Young Children

NCT ID: NCT04293328

Last Updated: 2022-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-07

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The two-year prospective study aims at investigating frequently replacement effect on myopia control in young children, and the use of weekly protein removal system in monthly replacement modality orthokeratology lenses on surface deposit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this two-year prospective study, low myopic children, aged 6-8 years, who have no prior experience in contact lens wear and myopia control treatment will be recruited. They will be prescribed with monthly replacement orthokeratology lenses for a period of one year. Axial elongation and ocular conditions during the study will be determined. Subjects will be randomly assigned to normal cleaning and intensive cleaning groups. Subjects in normal cleaning group will be provided with complimentary contact lenses solutions for daily cleaning and disinfection. In addition to the daily procedures for lens case, subjects in the intensive cleaning group will be required to perform weekly protein removal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopic Progression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

All subjects will be prescribed with monthly replacement orthokeratology for a period of 12 months. They will be randomly assigned to normal cleaning and intensive cleaning groups on 1:1 basis. All subjects follow the same daily cleaning procedures and subjects in intensive cleaning group will be required to perform weekly protein removal in addition to the daily routine.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Independent examiners will be responsible for the assessment of the primary outcomes, which are the axial length and surface coating.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monthly replacement lenses without protein removal

Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses

Group Type EXPERIMENTAL

orthokeratology

Intervention Type DEVICE

Nightly wear of orthokeratology lenses to correct vision in the daytime

Monthly replacement lenses with weekly protein removal

Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses

Group Type ACTIVE_COMPARATOR

orthokeratology

Intervention Type DEVICE

Nightly wear of orthokeratology lenses to correct vision in the daytime

Menicon Progent A+B

Intervention Type DEVICE

Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

orthokeratology

Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention Type DEVICE

Menicon Progent A+B

Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ortho-k Menicon Z Night lenses Menicon Z Night Toric lenses corneal reshaping therapy Menicon Progent Protein Remover for Rigid Gas Permeable Contact Lenses

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 6-10 years
* Normal ocular and general condition and not on medication which may contraindicate ortho-k lens wear
* Refractive sphere between -0.75 to -4.00 D, refractive cylinder ≤ -1.50 D and anisometropia ≤ -1.00 D
* Best correctable vision better than 0.08 logMAR in the worse eye
* Normal binocular function and accommodative status
* No prior experience in contact lens wear and myopia control treatment

Exclusion Criteria

* Strabismus at distance or near
* Contraindication for ortho-k lens wear
* Prior history of ocular surgery, trauma, or chronic ocular disease
* Systemic or ocular conditions that may interfere refractive development
* Systemic or ocular conditions that may interfere tear quality and contact lens wear
* Poor response to the use of study lenses
* Poor compliance to test procedures
* Poor compliance to the use of ortho-k lenses (e.g. use of solution, use of lenses)
* Poor compliance to follow-up schedule
Minimum Eligible Age

6 Years

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Menicon Co., Ltd.

INDUSTRY

Sponsor Role collaborator

The Hong Kong Polytechnic University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pauline Cho

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pauline Cho, PhD

Role: PRINCIPAL_INVESTIGATOR

The Hong Kong Polytechnic University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

School of Optometry, The Hong Kong Polytechnic University

Kowloon, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

References

Explore related publications, articles, or registry entries linked to this study.

Lee YC, Wang JH, Chiu CJ. Effect of Orthokeratology on myopia progression: twelve-year results of a retrospective cohort study. BMC Ophthalmol. 2017 Dec 8;17(1):243. doi: 10.1186/s12886-017-0639-4.

Reference Type BACKGROUND
PMID: 29216865 (View on PubMed)

Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye (Lond). 2012 Feb;26(2):185-93. doi: 10.1038/eye.2011.288. Epub 2011 Dec 2.

Reference Type BACKGROUND
PMID: 22134592 (View on PubMed)

Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012 Oct 11;53(11):7077-85. doi: 10.1167/iovs.12-10565.

Reference Type BACKGROUND
PMID: 22969068 (View on PubMed)

Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012 Jun 22;53(7):3913-9. doi: 10.1167/iovs.11-8453.

Reference Type BACKGROUND
PMID: 22577080 (View on PubMed)

Cheung SW, Boost MV, Cho P. Pre-treatment observation of axial elongation for evidence-based selection of children in Hong Kong for myopia control. Cont Lens Anterior Eye. 2019 Aug;42(4):392-398. doi: 10.1016/j.clae.2018.10.006. Epub 2018 Oct 24.

Reference Type BACKGROUND
PMID: 30366778 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSEARS20190926004-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Berkeley Orthokeratology Study
NCT00000123 COMPLETED PHASE3
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 ACTIVE_NOT_RECRUITING NA